TIDMAVCT

RNS Number : 4822J

Avacta Group PLC

12 September 2016

12 September 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Change of Adviser

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce the appointment of finnCap Ltd as Nominated Adviser and Broker to the Company with immediate effect.

ENDS

Notes to Editors

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                           Tel: +44 (0) 844 414 0452 
  Alastair Smith, Chief Executive            www.avacta.com 
  Officer 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                                Tel: +44 (0) 207 220 0500 
  Geoff Nash / Giles Rolls -                 www.finncap.com 
  Nominated Adviser 
  Tim Redfern / Alice Lane - 
  Corporate Broking                          Tel: +44 (0) 203 705 9318 
                                             Tel: +44 (0) 203 705 9217 
  WG Partners                                www.wgpartners.co.uk 
  David Wilson 
  Nigel Barnes 
  Claes Spang 
 
   FTI Consulting (Financial                  Tel: +44 (0) 203 727 1000 
   Media and IR)                              avacta@fticonsulting.com 
   Simon Conway / Natalie Garland-Collins 
 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPSSAFMUFMSESU

(END) Dow Jones Newswires

September 12, 2016 02:01 ET (06:01 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Avacta Charts.